Tessera Therapeutics grew their employee count by 50. The company’s technology can change base pairs, make small insertions or deletions, and integrate entire genes into the genome. Tessera Therapeutics s estimated revenue per employee is 142,367Tessera Therapeutics s total funding is 431.8M.Tessera Therapeutics s current valuation is 1.7B. McClintock’s contributions to genetics, as well as her intellectual tenacity, agility, and rigor, are an inspiration to everyone at Tessera. Patton as General Counsel and Secretary, effective today.Ms.
#Tessera therapeutics code
As the technology supports the design and testing of numerous natural and synthetic MGEs, Gene Writing™ is perceived to be more accurate and efficient than the existing gene correction techniques using CRISPR/Cas9 2.īy targeting DNA, the code of life and cause of genetic diseases, Gene Writing™ can write into or rewrite the genome to treat health conditions at their source. We are honored to launch Tessera Therapeutics close to the 118 th anniversary of Barbara McClintock’s birth. SOMERVILLE, Mass., Ap(GLOBE NEWSWIRE) - Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, announced the appointment of Cynthia M. Tessera is known for its next-generation gene correction technology platform called Gene Writing™, which utilizes Mobile Genetic Elements (MGEs) 1 to overcome the limitations of existing technology. Tessera recently secured $300 million in a Series C financing, the fourth stage of startup financing that focuses on scaling successful companies, where Hanwha Impact participated as an investor. The company was founded in 2018 by Flagship Pioneering, the investor behind COVID-19 vaccine maker Moderna. It provides gene writing and rewriting technologies that write and rewrite DNA to cure genetic diseases.
Hanwha Impact recently announced its investment in Tessera Therapeutics, an American life sciences company that is pioneering a new category of genome engineering technology and establishing a new field of genetic medicine. Tessera Therapeutics is a biotechnology company specializing in genetic medicine.
0 kommentar(er)
